LSC
GNMK

Lyon Street Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History

Lyon Street Capital’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-191,656
Closed -$790K – 91
2020
Q1 		$790K Buy
+191,656
New +$899K 1.26% 39
2018
Q4 		– Sell
-109,850
Closed -$807K – 61
2018
Q3 		$807K Buy
+109,850
New +$806K 0.5% 37

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Lyon Street Capital's GNMK Position: Q2 2020 in Review

Lyon Street Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 191,656 shares — an estimated $790K sold.

Lyon Street Capital first reported a position in GNMK in Q3 2018 and held it in 2 quarters. The position peaked at $807K in Q3 2018. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

  • Lyon Street Capital reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
  • Lyon Street Capital sold 191,656 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $790K.
  • Lyon Street Capital first reported a position in GenMark Diagnostics, Inc in Q3 2018 and held it in 2 quarters.
  • Lyon Street Capital's GenMark Diagnostics, Inc position peaked at $807K in Q3 2018.
  • 148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Lyon Street Capital's 13F filing for Q2 2020, filed 14 Aug 2020.